Beam Therapeutics Stock News

BEAM's novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations. While the 'standard' CRISPR-cas9 approach cuts double-stra

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

DekaBank Deutsche Girozentrale raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM) by 188.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,300 shares of the companys stock after purchasing an additional 10,000 shares during the quarter. DekaBank Deutsche Girozentrales holdings []

Spearhead Capital Advisors LLC lessened its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,552 shares of the company’s stock after selling 160 shares during the period. Spearhead Capital Advisors LLC’s holdings in Beam Therapeutics […]

CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a three-s

Beam (CURRENCY:BEAM) traded 7% lower against the dollar during the one day period ending at 23:00 PM Eastern on December 10th. During the last seven days, Beam has traded 20.5% lower against the dollar. One Beam coin can now be purchased for $0.67 or 0.00001388 BTC on cryptocurrency exchanges. Beam has a market capitalization of []

Beam Therapeutics Inc. (NASDAQ:BEAM)s stock price rose 9.1% on Tuesday . The stock traded as high as $76.19 and last traded at $75.19. Approximately 1,504 shares were traded during trading, a decline of 100% from the average daily volume of 839,615 shares. The stock had previously closed at $68.93. BEAM has been the topic of []

These eight stocks could rebound nicely over the next year and beyond.

In the last trading session, 0.98 million Beam Therapeutics Inc. (NASDAQ:BEAM) shares changed hands as the company’s beta touched 0. With the company’s per share price at $68.02 changed hands at -$4.54 or -6.26% during last session, the market valuation stood at $4.94B. BEAM’s last price was a discount, traded about -103.65% off its 52-week … Could Beam Therapeutics Inc. (NASDAQ: BEAM) Be The Biggest Winner? Read More »

Two big biotechs and one smaller one that could be winners over the long term.

Two big biotechs and one smaller one that could be winners over the long term.

Beam Therapeutics Inc. (NASDAQ:BEAM) was the target of a significant drop in short interest during the month of October. As of October 29th, there was short interest totalling 4,670,000 shares, a drop of 15.4% from the October 14th total of 5,520,000 shares. Currently, 9.4% of the companys stock are sold short. Based on an average []

Sana Biotechnology (NASDAQ:SANA) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk. Earnings & Valuation This table compares Sana Biotechnology and Beam Therapeutics revenue, earnings per share []

Analysts predict that Beam Therapeutics Inc. (NASDAQ:BEAM) will report earnings per share of ($0.94) for the current quarter, Zacks reports. Two analysts have made estimates for Beam Therapeutics earnings. The highest EPS estimate is ($0.35) and the lowest is ($1.15). Beam Therapeutics posted earnings of ($0.72) per share in the same quarter last year, which []

Can this high-flying gene-editing stock keep on climbing for new investors?